Baudax Stock Story

Baudax Bio Net Cash Flow from Financing is fairly stable at the moment as compared to the past year. Baudax Bio reported Net Cash Flow from Financing of 35.01 Million in 2021. Share Based Compensation is likely to rise to about 5.7 M in 2022, whereas Net Income Per Employee is likely to drop (266.6 K) in 2022. The fundamental goal of this short article is to break down our forecasting of Baudax for investors. We will try to forecast Baudax Bio outlook for September.
Published over a week ago
View all stories for Baudax Bio | View All Stories

Our current forecast of Baudax (NASDAQ:BXRX)

Baudax Bio is UNDERVALUED at 1.00 per share with modest projections ahead. About 20.0% of Baudax Bio shares are held by institutions such as insurance companies. Insiders ownership of Baudax Bio refers to the amount of Baudax Bio equity owned by Baudax officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Baudax, including its current ownership diagnostics.

How important is Baudax Bio's Liquidity

Baudax Bio financial leverage refers to using borrowed capital as a funding source to finance Baudax Bio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Baudax Bio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Baudax Bio's total debt and its cash.

How does Baudax utilize its cash?

To perform a cash flow analysis of Baudax Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Baudax Bio is receiving and how much cash it distributes out in a given period. The Baudax Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Baudax Bio Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Baudax Bio reported Net Cash Flow from Operations of (49.27 Million) in 2021

Acquisition by Dilmore Jillian of 15467 shares of Baudax Bio subject to Rule 16b-3

Legal trades by Baudax Bio insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Baudax insider trading alert for grant of common stock by Dilmore Jillian, Corporate ControllerSecretary, on 17th of June 2022. This event was filed by Baudax Bio Inc with SEC on 2022-06-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Baudax Bio exhibits very low volatility with skewness of -2.28 and kurtosis of 10.16. However, we advise investors to further study Baudax Bio technical indicators to make sure all market info is available and is reliable. Baudax Bio is a potential penny stock. Although Baudax Bio may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Baudax Bio. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Baudax instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Margin Breakdown

EBITDA Margin(13.17)
Gross Margin(1.37)
Profit Margin(19.95)

Will Baudax investors exit after the slide?

Current total risk alpha is at -0.94. Baudax Bio exhibits very low volatility with skewness of -2.28 and kurtosis of 10.16. However, we advise investors to further study Baudax Bio technical indicators to make sure all market info is available and is reliable. Baudax Bio is a potential penny stock. Although Baudax Bio may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Baudax Bio. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Baudax instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Takeaway on Baudax Bio Investment

While many other companies in the biotechnology industry are either recovering or due for a correction, Baudax Bio may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 6th of August 2022, our research shows that Baudax Bio is a rather extremely dangerous investment opportunity with a close to average odds of financial distress in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our primary 90 days buy-or-sell advice on the company is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Baudax Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com